Pharmacokinetics of a sustained release formulation of PDGFβ-receptor directed carrier proteins to target the fibrotic liver

被引:23
|
作者
van Dijk, F. [1 ,2 ]
Teekamp, N. [1 ]
Beljaars, L. [2 ]
Post, E. [2 ]
Zuidema, J. [3 ]
Steendam, R. [3 ]
Kim, Y. O. [4 ]
Frijlink, H. W. [1 ]
Schuppand, D. [4 ,5 ]
Poelstra, K. [2 ]
Hinrichs, W. L. J. [1 ]
Olinga, P. [1 ]
机构
[1] Univ Groningen, Groningen Res Inst Pharm, Dept Pharmaceut Technol & Biopharm, Groningen, Netherlands
[2] Univ Groningen, Groningen Res Inst Pharm, Dept Pharmacokinet Toxicol & Targeting, Groningen, Netherlands
[3] InnoCore Pharmaceut, Groningen, Netherlands
[4] Johannes Gutenberg Univ Mainz, Univ Med Ctr, Res Ctr Immune Therapy, Inst Translat Immunol, Mainz, Germany
[5] Harvard Med Sch, Beth Israel Deaconess Med Ctr, Boston, MA USA
关键词
Controlled release; Biodegradable polymeric microspheres; PDGF beta-receptor targeted drug carrier; Protein delivery; in vitro in vivo correlation; Liver fibrosis; GROWTH-FACTOR RECEPTOR; DRUG-DELIVERY; ANTIFIBROTIC THERAPIES; POLYMERIC MICROSPHERES; MULTIBLOCK-COPOLYMER; INTERFERON-GAMMA; IN-VIVO; FIBROSIS; IMPLANTS; MICE;
D O I
10.1016/j.jconrel.2017.11.029
中图分类号
O6 [化学];
学科分类号
0703 ;
摘要
Liver fibrogenesis is associated with excessive production of extracellular matrix by myofibroblasts that often leads to cirrhosis and consequently liver dysfunction and death. Novel protein-based antifibrotic drugs show high specificity and efficacy, but their use in the treatment of fibrosis causes a high burden for patients, since repetitive and long-term parenteral administration is required as most proteins and peptides are rapidly cleared from the circulation. Therefore, we developed biodegradable polymeric microspheres for the sustained release of proteinaceous drugs. We encapsulated the drug carrier pPB-HSA, which specifically binds to the PDGF beta R that is highly upregulated on activated myofibroblasts, into microspheres composed of hydrophilic multi-block copolymers composed of poly(L-lactide) and poly ethylene glycol/poly(is an element of-caprolactone), allowing diffusion-controlled release. Firstly, we estimated in mice with acute fibrogenesis induced by a single CCl4 injection the half-life of I-125-labeled pPB-HSA at 40 min and confirmed the preferential accumulation in fibrotic tissue. Subsequently, we determined in the Mdr2-/- mouse model of advanced biliary liver fibrosis how the subcutaneously injected microspheres released pPB-HSA into both plasma and fibrotic liver at 24 h after injection, which was maintained for six days. Although the microspheres still contained protein at day seven, pPB-HSA plasma and liver concentrations were decreased. This reduction was associated with an antibody response against the human albumin-based carrier protein, which was prevented by using a mouse albumin-based equivalent (pPB-MSA). In conclusion, this study shows that our polymeric microspheres are suitable as sustained release formulation for targeted protein constructs such as pPB-HSA. These formulations could be applied for the long-term treatment of chronic diseases such as liver fibrosis.
引用
收藏
页码:258 / 265
页数:8
相关论文
共 50 条
  • [1] Polymeric microspheres for the sustained release of a protein-based drug carrier targeting the PDGFβ-receptor in the fibrotic kidney
    Teekamp, N.
    Van Dijk, F.
    Broesder, A.
    Evers, M.
    Zuidema, J.
    Steendam, R.
    Post, E.
    Hillebrands, J. L.
    Frijlink, H. W.
    Poelstra, K.
    Beljaars, L.
    Olinga, P.
    Hinrichs, W. L. J.
    INTERNATIONAL JOURNAL OF PHARMACEUTICS, 2017, 534 (1-2) : 229 - 236
  • [2] Therapeutic proteins in the treatment of liver fibrosis: the antifibrotic potential of a sustained release formulation for a PDGFβ-receptor targeted rho-kinase inhibitor
    van Dijk, Fransien
    Teekamp, Naomi
    Beljaars, Leonie
    Post, Eduard
    Kim, Yong Ook
    Frijlink, Erik
    Hinrichs, Wouter
    Schuppan, Detlef
    Poelstra, Klaas
    Olinga, Peter
    HEPATOLOGY, 2017, 66 : 217A - 217A
  • [3] The antifibrotic potential of a sustained release formulation of a PDGFβ-receptor targeted rho kinase inhibitor
    van Dijk, F.
    Teekamp, N.
    Post, E.
    Schuppan, D.
    Kim, Y. O.
    Zuidema, J.
    Steendam, R.
    Klose, Matthias H. M.
    Meier-Menches, Samuel M.
    Casini, A.
    Horvatovich, P. L.
    Sijbrandi, N. J.
    Frijlink, H. W.
    Hinrichs, W. L. J.
    Poelstra, K.
    Beljaars, L.
    Olinga, P.
    JOURNAL OF CONTROLLED RELEASE, 2019, 296 : 250 - 257
  • [4] PHARMACOKINETICS OF A SUSTAINED-RELEASE THEOPHYLLINE FORMULATION
    TREMBATH, PW
    BOOBIS, SW
    BRITISH JOURNAL OF CLINICAL PHARMACOLOGY, 1980, 9 (04) : 365 - 369
  • [5] Formulation strategies for sustained release of proteins
    Lewis, Andrew L.
    Illum, Lisbeth
    THERAPEUTIC DELIVERY, 2010, 1 (03) : 457 - 479
  • [6] Pharmacokinetics and bioavailability of sustained release and conventional formulation of acyclovir
    Jun, HZ
    Jia, BZ
    Xi, JC
    Rong, Z
    Yan, YG
    Zhi, HW
    Kun, C
    Xiang, YX
    EUROPEAN JOURNAL OF DRUG METABOLISM AND PHARMACOKINETICS, 2001, 26 (03) : 145 - 148
  • [7] PHARMACOKINETICS OF A SUSTAINED-RELEASE TRIMAZOSIN TABLET FORMULATION
    FLOUVAT, B
    FODOR, F
    ROUX, A
    BIANCHINE, JR
    AMERICAN HEART JOURNAL, 1983, 106 (05) : 1228 - 1234
  • [8] Pharmacokinetics and bioavailability of sustained release and conventional formulation of acyclovir
    Jun Hong Zhang
    Jia Bi Zhu
    Xi Jing Chen
    Rong Zhao
    Yan Yun Gang
    Zhi Hong Wu
    Kun Cheng
    Xiang Yang Xu
    European Journal of Drug Metabolism and Pharmacokinetics, 2001, 26 : 145 - 148
  • [9] Carbon Nanotube: A Novel Carrier for Sustained Release Formulation
    Shah, Malay
    Agrawal, Yadvendra
    FULLERENES NANOTUBES AND CARBON NANOSTRUCTURES, 2012, 20 (08) : 696 - 708
  • [10] Pharmacokinetics of Paclimer™ microspheres:: A sustained release formulation of paclitaxel.
    Fredrickson, J
    Burak, E
    Foster, F
    Gillespie, W
    Shafer, S
    CLINICAL PHARMACOLOGY & THERAPEUTICS, 2000, 67 (02) : 101 - 101